Falk takes on Lipid's ulcerative colitis lead in EU while search for US partner goes on
This article was originally published in Scrip
Dr Falk Pharma has formally exercised its option on Lipid Therapeutics' lead product, LT-02, for ulcerative colitis. The German companies signed a co-development and option-agreement in 2009. Falk is now assuming full responsibility for the further development and commercialisation of LT-02 in Europe, with a Phase III induction trial in ulcerative colitis planned to start in the second half of 2012.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.